Log on/register
BioMed Central home | Journals A-Z | Feedback | Support | My details
Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T
Cardiovasc Diabetol 2007, 6:12
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.


Original investigation    
Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothelial cells
Tang R, Li Q, Lv L, Dai H, Zheng M, Ma K, Liu B
Cardiovascular Diabetology 2010, 9:31 (27 July 2010)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles]
2.


Research article    
Metabolic effects of an AT1-receptor blockade combined with HCTZ in cardiac risk patients: a non interventional study in primary care
Bramlage P, Schönrock E, Odoj P
BMC Cardiovascular Disorders 2008, 8:30 (10 November 2008)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
3.


Original investigation    
Effect of the angiotensin receptor blocker irbesartan on metabolic parameters in clinical practice: the DO-IT prospective observational study
Parhofer KG, Münzel F, Krekler M
Cardiovascular Diabetology 2007, 6:36 (27 November 2007)
 [Abstract] [Full Text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]

This article is also cited by a further 4 articles in PubMed Central


You can also check ISI Web of Science for additional citations (subscription required)
printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2010 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.